drugset

drugset / Trial / NCT04216693

Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)

NCT04216693 ↗

Phase 2 Withdrawn The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Yale University · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.

Timeline

Start: 2020-06-01
Primary completion: 2022-12-01
Completion: 2023-06-01

Publications

Results Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Starkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1alpha Transactivation in Steatohepatitis. Cell Metab. 2018 Feb 6;27(2):339-350.e3. doi: 10.1016/j.cmet.2018.01.007.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Digoxin	Other / unclassified	0.0625 mg	Oral
Subject	Digoxin	Other / unclassified	0.125 mg	Oral
Subject	Digoxin	Other / unclassified	0.25 mg	Oral

Indications